| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786016 | Clinical Oncology | 2018 | 9 Pages |
Abstract
There are limited, retrospective data on the overall activity and safety of EBRT in GEPNETS. EBRT generally seems to be well tolerated in selected PNET patients with encouraging activity. Well-designed prospective studies in clearly defined populations are required to clarify the role of EBRT in neuroendocrine tumours.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.L. Chan, R. Thompson, M. Lam, N. Pavlakis, J. Hallet, C. Law, S. Singh, S. Myrehaug,